Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
cancer
daniel o'day
2
×
deals
life sciences
national blog main
national top stories
new york blog main
san francisco blog main
abbvie
allergan aesthetics
alzheimer's disease
amgen
astrazeneca
athira pharma
attralus
biontech
boehringer ingelheim
boston
boulder/denver blog main
boulder/denver top stories
cancer drugs
cancer immunotherapy
center for medicare and medicaid services
chiesi farmaceutici
cholestatic liver diseases
click therapeutics
companion diagnostic
covid-19
cullinan oncology
cystic fibrosis
detroit blog main
detroit top stories
diabetic macular edema
diagnostics
dogma therapeutics
dyne therapeutics
eli lilly
What
acquire
acquisitions
agreed
big
biggest
billion
bio
broad
build
buy
ceo
company’s
confidence
daniel
debut
didn’t
drug
dyne’s
foundation
gain
genentech
gilead
medicine
microbiome
momentum
morning
moves
openly
o’day
panels
pay
pays
picked
pipeline
profiling
recently
redux
remaining
rest
roche
Language
unset
Current search:
" daniel o'day "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
